Table 2 Immuno- and cell-based therapy in pediatric oncology
Disease | Drug | Target |
|---|---|---|
1. Innate immunity | ||
 1.1 osteosarcoma | Mifamurtide | NOD2 |
2. Humoral immunity | ||
 2.1 Neuroblastoma | Dinutuximab | GD2 |
 2.2 NHL and PTLD | Rituximab | CD20 |
 2.3 HL and ALCL | Brentuximab | CD30 |
3. Cellular immunity | ||
 3.1 AML | DLI | Multiple |
 3.2 ALL | CAR T-cells | CD19 |
 3.3 Ewing sarcoma | TCR T-cells | CHM1 |